CABA vs NTLA
CABA: Cabaletta Bio is a clinical-stage biotechnology firm developing one-time, curative CAR T cell therapies aimed at resetting the immune system for patients with complex autoimmune diseases. NTLA: CRISPR-based genome editing company developing in vivo therapies for rare genetic diseases including hereditary angioedema and ATTR amyloidosis.
Side-by-side fundamentals
| Metric | CABA | NTLA | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $2.75 | $11.13 | |
| Market cap as of 2026-07-23 | $449M | $1.6B | |
| Net margin as of 2026-07-23 | n/a | -597.0% | |
| Operating margin as of 2026-07-23 | n/a | -636.6% | |
| ROE as of 2026-07-23 | -131.6% | -57.3% | NTLA higher |
| ROA as of 2026-07-23 | -96.5% | -46.1% | NTLA higher |
| Debt / equity as of 2026-07-23 | 0.23 | 0.00 | NTLA lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +45.0% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +9.1% | |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-07-23 | 3.27 | 1.78 | |
| 1-year return as of 2026-07-22 close | +72.0% | -17.5% | CABA higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.